Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio

U.S. patent allowance for SPC-15 strengthens Silo Pharma’s PTSD-focused intellectual property alongside an already issued Japanese patent.

Rhea-AI Summary

Silo Pharma (SILO) received a U.S. Patent and Trademark Office Notice of Allowance for a patent application covering its lead PTSD asset, SPC-15. The patent, titled “Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior,” includes composition and method claims for an intranasal therapeutic targeting PTSD. A corresponding patent has already been issued in Japan, and the company reports that its biopharmaceutical portfolio includes numerous issued and allowed patents.

Positive

• USPTO Notice of Allowance for SPC-15 patent application covering PTSD intranasal therapeutic
• Japanese patent already issued for the same SPC-15 invention
• Portfolio breadth includes numerous issued and allowed biopharmaceutical patents

Negative

• None.

News Explained

Silo reports that the USPTO has issued a Notice of Allowance for SPC-15’s U.S. patent application; the application has cleared examination and should be granted shortly, so the disclosed status is an allowed application rather than an issued U.S. patent.

Market Context

On Aug 18, 2026, Silo recorded a 7.82% 24-hour decline after a Canadian patent allowance; the U.S. a...

Analysis

On Aug 18, 2026, Silo recorded a 7.82% 24-hour decline after a Canadian patent allowance; the U.S. allowance marked another jurisdictional step for the same SPC-15 program.

Historical Context

2 past events · Latest: Aug 18

2 events

1. Aug 18

   Canadian patent allowance

   24h Move

   -7.8%

   Canadian Notice of Allowance covered SPC-15 methods for stress-induced psychiatric disorders.

2. Aug 10

   European patent grant

   24h Move

   +1.2%

   European patent granted coverage for SPC-15’s preventative PTSD treatment approach.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

notice of allowance, USPTO, intranasal, patentability

4 terms

notice of allowance regulatory

"the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance"

A notice of allowance is an official confirmation from a patent office that a patent application has met all necessary requirements and is approved for granting. It signals that the invention is likely to receive legal protection soon, which can be important for investors considering the value and exclusivity of a new product or technology. Think of it as a green light indicating that the invention is on track to become legally protected.

USPTO regulatory

"the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance"

United States Patent and Trademark Office (USPTO) is the federal agency that reviews and issues patents for inventions and registers trademarks for brand names and logos. For investors, USPTO decisions act like a gatekeeper for a company’s legal right to exclude competitors — similar to a property deed for ideas and brands — which can protect revenue, support pricing power, and affect a company’s long‑term value and risk profile.

intranasal medical

"a novel intranasal therapeutic targeting post-traumatic stress disorder (PTSD)"

Administration or delivery of a drug or vaccine through the nose, typically via a spray or drops that are absorbed by the nasal tissues. For investors, intranasal products can matter because they often offer easier, needle-free use, faster onset of effect, and potential cost or compliance advantages that can widen a product’s market and affect regulatory review, manufacturing complexity, and commercial prospects — similar to how a convenient app can outsell a clunky desktop program.

patentability regulatory

"the application meets the requirements for patentability and should be granted shortly"

Patentability is whether an invention can legally receive a patent — meaning it is new, useful, and not an obvious change from what already exists. For investors, patentability matters because a granted patent acts like a temporary monopoly on a product or process, helping protect potential revenue and making a company’s future cash flows and competitive position more predictable, much like a fence around a valuable plot of land.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Allowed claims cover compositions and methods for preventing or mitigating stress-induced behavioral responses

SARASOTA, FLA., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems with a wholly owned managed AI agent platform, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15, a novel intranasal therapeutic targeting post-traumatic stress disorder (PTSD).

The invention, titled “Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior,” is also covered by a corresponding patent issued by the Japan Patent Office earlier this year.

Silo’s Chief Executive Officer Eric Weisblum commented, “Securing U.S. patent protection for this invention is an important component of our strategy for SPC-15 as we advance the drug’s development for PTSD,” said Eric Weisblum, Chief Executive Officer of Silo Pharma. “The allowed application is directed to both composition and method claims related to our proprietary therapeutic approach to preventing or delaying behavioral responses associated with stress-induced behavioral responses.”

A Notice of Allowance indicates that the patent office has completed its examination and determined that the application meets the requirements for patentability and should be granted shortly.

Silo’s biopharmaceutical intellectual property portfolio currently holds numerous issued and allowed patents.

About Silo Pharma, Inc.

Silo Pharma is a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for post-traumatic stress disorder (PTSD), SP-26 for fibromyalgia and chronic pain, and a preclinical asset targeting Alzheimer’s disease. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com

QwikAgents, Silo Pharma's wholly owned artificial intelligence subsidiary, is a managed AI agent platform that delivers dedicated autonomous agents for research, content generation, scheduling, and workflow automation each running in a persistent environment with proprietary smart-routing across multiple AI models. The subsidiary reflects Silo's strategy to expand into high-growth technology markets while continuing to advance its core biopharmaceutical pipeline. qwikagents.com

Forward Looking Statements

This news release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements about changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.

Contact

(800) 705-0120
investors@silopharma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the USPTO Notice of Allowance mean for Silo Pharma’s SPC-15 patent?

A Notice of Allowance means the U.S. Patent and Trademark Office has completed its examination and determined that the SPC-15 application meets patentability requirements and should be granted shortly.

What types of claims are included in the allowed SPC-15 patent application?

The allowed application includes composition and method claims related to Silo Pharma’s proprietary therapeutic approach to preventing or delaying behavioral responses associated with stress-induced behavioral responses.

Which markets currently recognize patent protection for the SPC-15 invention?

The SPC-15 invention is covered by a U.S. patent allowance and a corresponding patent issued by the Japan Patent Office earlier in the year.